SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CGNE CALGENE
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: celeryroot.com who wrote (45)1/30/1997 11:11:00 AM
From: Bhag Karamchandani   of 76
 
I am no expert and merely a sideline watcher but find it really exploitative for Monsanto to acquire a majority stake at a higher price than their current bid- when CGNE was at that time in much worse shape, financially speaking , and with fewer patents to their credit.

I think that if I was an investor, I would be interested in a class action. I wonder what the investors who poured hundreds of millions of dollars into CGNE's R&D feel about the offerred price of 7.50- I believe that the single most important reason behind CGNE's down fall was a monumentally disastrous execution of their genetically altered FLVRSVR tomato product to market. Their total array of R&D is very solid - specially in terms of its tremendous medium term commerciual potential in the hundreds of millions of dollars. Monsanto's offerred price for CGNE technology is small crumbs to a financially famished stockholder community.

A non- shareholders opinion.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News